Oncolytics Biotech (TSE:ONC) Insider Jared Ryan Kelly Purchases 29,500 Shares

Oncolytics Biotech Inc. (TSE:ONC) insider Jared Ryan Kelly bought 29,500 shares of the company’s stock in a transaction dated Thursday, February 12th. The shares were purchased at an average cost of C$1.16 per share, with a total value of C$34,220.00. Following the acquisition, the insider directly owned 109,000 shares of the company’s stock, valued at approximately C$126,440. This represents a 37.11% increase in their position.

Jared Ryan Kelly also recently made the following trade(s):

• On Wednesday, February 11th, Jared Ryan Kelly bought 5,600 shares of Oncolytics Biotech stock. The stock was acquired at an average cost of C$1.15 per share, with a total value of C$6,440.00.

Oncolytics Biotech Trading Down 1.3%

ONC stock opened at C$14.90 on Friday. Oncolytics Biotech Inc. has a 52 week low of C$0.44 and a 52 week high of C$2.08. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The company’s 50-day simple moving average is C$14.90 and its 200 day simple moving average is C$13.03. The company has a market capitalization of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80.

Oncolytics Biotech (TSE:ONC) last posted its quarterly earnings data on Wednesday, November 12th. The company reported C($0.14) earnings per share (EPS) for the quarter. As a group, sell-side analysts anticipate that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.